1234319-14-2

Basic information

• Product Name: 2-(4-(DifluoroMethyl)phenyl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane
• Synonyms: 2-(4-(DifluoroMethyl)phenyl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane;1,3,2-Dioxaborolane, 2-[4-(difluoromethyl)phenyl]-4,4,5,5-tetramethyl-
• CAS NO: 1234319-14-2
• Molecular Formula: C₁₃H₁₇BF₂O₂
• Molecular Weight: 254.0806864
• Mol File: 1234319-14-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-(4-(DifluoroMethyl)phenyl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-(DifluoroMethyl)phenyl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane(1234319-14-2)
• EPA Substance Registry System: 2-(4-(DifluoroMethyl)phenyl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane(1234319-14-2)

Safety Data

• Hazardous Substances Data: 1234319-14-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-(4-(DifluoroMethyl)phenyl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane is used as a reagent in Suzuki-Miyaura cross-coupling reactions, a widely employed method for the formation of carbon-carbon bonds in organic synthesis. Its high reactivity and selectivity make it a preferred choice for the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-(4-(DifluoroMethyl)phenyl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane is used as a building block for the preparation of various pharmaceuticals. The difluoromethyl group in its structure is a valuable functional group that can be incorporated into drug molecules to modulate their properties, such as solubility, stability, and biological activity.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, 2-(4-(DifluoroMethyl)phenyl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane is utilized as a building block for the synthesis of agrochemicals. The incorporation of the difluoromethyl group can enhance the efficacy and selectivity of agrochemicals, making them more effective in controlling pests and diseases in agriculture.

Upstream product

• 51776-71-7 p-bromo-α,α-difluorotoluene 
• 73183-34-3 bis(pinacol)diborane 
• 1122-91-4 4-bromo-benzaldehyde 
• 1511-62-2 bromodifluoromethane 
• 68716-49-4 p-bromophenylboronic acid pinacol ester 
• 128376-64-7 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde 

Downstream Products

• 1377503-26-8 (S)-methyl 2-(tert-butoxy)-2-(4-(4-(difluoromethyl)phenyl)-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-b]pyridin-3-yl)acetate 
• 1377503-01-9 (S)-2-(tertbutoxy)-2-(4-(4-(difluoromethyl)phenyl)-2-methyl-5,6,7,8-tetrahvdrobenzo[4,5]thieno[2,3-b]pyridin-3-yl)acetic acid 
• 1464150-90-0 (4-(3-(4-(difluoromethyl)phenyl)imidazo[1,2-a]pyrazin-6-yl)phenyl)(4-methylpiperazin-1-yl)methanone 
• 1354286-49-9 N-(5-(4-(difluoromethyl)phenyl)-2-morpholinopyridin-4-yl)-5,7-difluoro-3-methyl-2-(pyridin-2-yl)quinolin-4-amine 

Relevant articles and documents

Accessing Difluoromethylated and Trifluoromethylated cis-Cycloalkanes and Saturated Heterocycles: Preferential Hydrogen Addition to the Substitution Sites for Dearomatization

Reported here is a straightforward process in which a cyclic (alkyl)(amino)carbene/Rh catalyst system facilitates the preferential addition of hydrogen to the substitution sites of difluoromethylated and trifluoromethylated arenes and heteroarenes, leading to dearomative reduction. This strategy enables the diastereoselective synthesis of cis-difluoromethylated and cis-trifluoromethylated cycloalkanes and saturated heterocycles, and even allows formation of all-cis multi-trifluoromethylated cyclic products with a defined equatorial orientation of the di- and trifluoromethyl groups. Deuterium-labeling studies indicate that hydrogen preferentially attacks the substitution sites of planar arenes, resulting in dearomatization, possibly with heterogeneous Rh as the reactive species, followed by either reversible or irreversible hydrogen addition to the nonsubstitution sites.

A fluorine-containing methyl compounds and its preparation method (by machine translation)

The invention discloses a fluorine-containing methyl compounds and its preparation method. The invention provides a fluorine-containing shown as formula C methyl compounds, wherein R is aryl group containing, or, containing a hetero aryl group, and the aryl group or the heteroaryl on the aromatic carbon atom and CFm Hn Connected, m is 1 or 2, m + n=3. The compounds according to the prior art is difficult to make, the preparation method of the raw material and the catalyst are the ordinary industrial raw materials, cheap and easy to obtain, high reaction efficiency, high yield, after treatment is simple, low toxicity, environmental protection, functional group compatibility is good, broad-spectrum is strong, the production cost is low, it has very good market application prospect. (by machine translation)

Metallaphotoredox Difluoromethylation of Aryl Bromides

Herein, we report a convenient and broadly applicable strategy for the difluoromethylation of aryl bromides by metallaphotoredox catalysis. Bromodifluoromethane, a simple and commercially available alkyl halide, is harnessed as an effective source of difluoromethyl radical by silyl-radical-mediated halogen abstraction. The merger of this fluoroalkyl electrophile activation pathway with a dual nickel/photoredox catalytic platform enables the difluoromethylation of a diverse array of aryl and heteroaryl bromides under mild conditions. The utility of this procedure is showcased in the late-stage functionalization of several drug analogues.

4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND 6-AMINO-2-(4-SUBSTITUTED-PHENYL)-PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES

Provided herein are 4-amino-6-(4-substituted-phenyl)-picolinic acids and their derivatives, and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylic acids and their derivatives, compositions comprising the acids and their derivatives, and methods of use thereof as herbicides.

Imidazo[5,1-f][1,2,4]Triazines for the Treatment of Neurological Disorders

The present invention relates to compounds of the Formula and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal.

HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

2-PYRIDONE COMPOUNDS

A 2-pyridone compound represented by the formula [1]: {wherein in the formula [1], the ring represented by A represents a benzene ring or a pyridine ring, X represents any of the structures represented by the formulas [3] shown below: V represents a single bond or a lower alkylene group, and W represents a single bond, an ether bond or a lower alkylene group (wherein the lower alkylene group may contain an ether bond)}, a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is a compound that has an excellent GK activating effect and is useful as a pharmaceutical.